Concepedia

PharmGKB summary

Caroline F. Thorn, Sharon Marsh, Michelle Whirl‐Carrillo, Howard L. McLeod, Teri E. Klein, Russ B. Altman

Pharmacogenetics and Genomics · 2010 · 128 citations · 44 references

DOIFull text

Open access

Concepts

Abstract

Thorn, Caroline F.a; Marsh, Sharond; Carrillo, Michelle Whirla; McLeod, Howard L.c; Klein, Teri E.a; Altman, Russ B.a,b Author Information

References

44

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

Masanori Miwa, Masako Ura, M Nishida et al. · European Journal of Cancer · 1998 · 1.2K citations

, , +12

Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy

Sheeja T. Pullarkat, Jan Stoehlmacher, Viviane S. Ghaderi et al. · The Pharmacogenomics Journal · 2001 · 573 citations

, , +13

Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer

James J. Farrell, Hany Elsaleh, M. López García et al. · Gastroenterology · 2008 · 450 citations · Full text

, , +9

Role of Genetic and Nongenetic Factors for Fluorouracil Treatment-Related Severe Toxicity: A Prospective Clinical Trial by the German 5-FU Toxicity Study Group

Matthias Schwab, Ulrich M. Zanger, Claudia Marx et al. · Journal of Clinical Oncology · 2008 · 394 citations · Full text

, , +17

Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity

G. Milano, M C Etienne, Muriel Barberi‐Heyob et al. · British Journal of Cancer · 1999 · 276 citations · Full text

, , +13